Immunis Nominated for Prix Galien Award for “Best Startup”

IRVINE, Calif.--()--Immunis, Inc., a private biotech company pioneering a novel secretome-based therapy for age and disease-related immune decline, is thrilled to announce its nomination for the prestigious Prix Galien Award for "Best Startup."

Recognized globally as “the equivalent of the Nobel Prize in the field of biopharmaceutical research,” the Prix Galien Awards acknowledge the game-changers and innovative leaders within the industry. The nomination underlines the remarkable contribution of Immunis to the scientific community through its cellular secretome aimed to ameliorate muscle atrophy associated with knee osteoarthritis. Immunis is honored to be recognized for its unwavering commitment to transforming lives through cutting-edge biotechnologies.

As we eagerly look forward to the grand award ceremony to be held at the iconic New York City Natural History Museum in October, we wish to express our immense gratitude for this recognition.

“To be nominated for such a distinguished honor validates the hard work, dedication, and innovative spirit that fuels Immunis,” says Immunis Chairman Dr. Hans Keirstead. “We share this excitement with our dedicated team, esteemed partners, and everyone who believes in our mission to revolutionize healthcare solutions. Stay tuned as we continue this exciting journey, striving for excellence, innovation, and making a positive global impact.”

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit:

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.